search
Back to results

High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors

Primary Purpose

Solid Tumors, Brain Tumors

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Amifostine
Sponsored by
Children's Hospital Medical Center, Cincinnati
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumors focused on measuring Solid Tumors, Brain Tumors

Eligibility Criteria

undefined - 30 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • High risk Ewing's Sarcoma Family Tumors (ESFT) including Ewing's Sarcoma, Askin's tumor, peripheral PNET
  • High risk desmoplastic small round cell tumors (DSRCT)
  • Relapsed Wilm's tumor, diffuse anaplastic Wilm's tumor
  • High risk brain tumors including PNET/Medulloblastomas/germinomas
  • Relapsed germ cell tumors
  • Metastatic or relapsed rhabdoid tumors
  • Other relapsed/refractory pediatric embryonal tumors
  • Less than 30 years of age
  • Performance >= 50%
  • Cancer Diagnosis verification and staging
  • Disease Response and Recovery
  • Adequate Organ Function (Renal, Liver, Cardiac)

Exclusion Criteria:

  • Uncontrolled Infection
  • Pregnancy or Breastfeeding (For Females)
  • Disease Progression
  • Uncontrolled Intercurrent Illness
  • HIV Positive
  • Receiving other Investigational Agents
  • Amifostine Allergy

Sites / Locations

  • Cincinnati Children's Hospital Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Amifostine

Arm Description

Outcomes

Primary Outcome Measures

Incidence of Bacteriemia in a High Dose Busulfan, Melphalan and Thiotepa Chemotherapy Regimen With Autologous Peripheral Blood Stem Cell Rescue in Patients With High Risk and Relapsed or Refractory Pediatric Solid Tumors

Secondary Outcome Measures

Full Information

First Posted
August 1, 2012
Last Updated
December 29, 2021
Sponsor
Children's Hospital Medical Center, Cincinnati
search

1. Study Identification

Unique Protocol Identification Number
NCT05167370
Brief Title
High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors
Official Title
High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Terminated
Why Stopped
The study was terminated as recommended by the DSMB due to inability to meet enrollment goals within the time frame allotted (target of 25 patients over 5 years).
Study Start Date
December 13, 2010 (Actual)
Primary Completion Date
April 29, 2011 (Actual)
Study Completion Date
April 24, 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Children's Hospital Medical Center, Cincinnati

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a study of amifostine to determine how effective it is in the reduction of infection in a high dose chemotherapy regimen with autologous stem cell rescue in children with high risk, relapsed or refractory pediatric solid tumors.
Detailed Description
Autologous stem cell transplant (ASCT) permits chemotherapy dose-escalation to exploit the steep dose-response of solid tumors to alkylating agents. Although ASCT regimens have activity in some high risk pediatric solid tumors, non-hematological regimen-related morbidity and mortality are major barriers to additional dose escalation. We hypothesized that the chemoprotectant amifostine (Ethyol®) would reduce the toxicity of ASCT without compromising anti-tumor efficacy. This is a study of amifostine at 1125 mg/m2 to determine the efficacy of it's chemoprotection in the reduction of bacteremia in a high dose busulfan, melphalan and thiotepa chemotherapy regimen with autologous stem cell rescue in children with high risk, relapsed or refractory pediatric solid tumors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumors, Brain Tumors
Keywords
Solid Tumors, Brain Tumors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Amifostine
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Amifostine
Other Intervention Name(s)
Ethyol
Intervention Description
Amifostine (Ethyol) 1125 mg/m2 will be given intravenously daily over 5 minutes starting 30 minutes prior to chemotherapy (melphalan or thiotepa) on days -5, -4, -3, -2, and on day -1 twenty four hours after prior dose of amifostine.
Primary Outcome Measure Information:
Title
Incidence of Bacteriemia in a High Dose Busulfan, Melphalan and Thiotepa Chemotherapy Regimen With Autologous Peripheral Blood Stem Cell Rescue in Patients With High Risk and Relapsed or Refractory Pediatric Solid Tumors
Time Frame
3 months

10. Eligibility

Sex
All
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: High risk Ewing's Sarcoma Family Tumors (ESFT) including Ewing's Sarcoma, Askin's tumor, peripheral PNET High risk desmoplastic small round cell tumors (DSRCT) Relapsed Wilm's tumor, diffuse anaplastic Wilm's tumor High risk brain tumors including PNET/Medulloblastomas/germinomas Relapsed germ cell tumors Metastatic or relapsed rhabdoid tumors Other relapsed/refractory pediatric embryonal tumors Less than 30 years of age Performance >= 50% Cancer Diagnosis verification and staging Disease Response and Recovery Adequate Organ Function (Renal, Liver, Cardiac) Exclusion Criteria: Uncontrolled Infection Pregnancy or Breastfeeding (For Females) Disease Progression Uncontrolled Intercurrent Illness HIV Positive Receiving other Investigational Agents Amifostine Allergy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sonata Jodele, MD
Organizational Affiliation
CCHMC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cincinnati Children's Hospital Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States

12. IPD Sharing Statement

Learn more about this trial

High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors

We'll reach out to this number within 24 hrs